Control of mucocutaneous leishmaniasis, a neglected disease: results of a control programme in Satipo Province, Peru.
Authors
Guthmann, J PArlt, D
Garcia, L M L
Rosales, M
de Jesus Sanchez, J
Alvarez, E
Lonlas, S
Conte, M
Bertoletti, G
Fournier, C
Huari, R
Torreele, E
Llanos-Cuentas, A
Affiliation
Epicentre, Paris, France. jguthmann@epicentre.msf.orgIssue Date
2005-09
Metadata
Show full item recordAbstract
Mucocutaneous leishmaniasis (MCL) is an important health problem in many rural areas of Latin America, but there are few data on the results of programmatic approaches to control the disease. We report the results of a control programme in San Martin de Pangoa District, which reports one of the highest prevalences of MCL in Peru. For 2 years (2001--2002), the technicians at the health post were trained in patient case management, received medical support and were supplied with antimonials. An evaluation after 2 years showed the following main achievements: better diagnosis of patients, who were confirmed by microscopy in 34% (82/240) of the cases in 2001 and 60% of the cases (153/254) in 2002; improved follow-up during treatment: 237 of 263 (90%) patients who initiated an antimonial therapy ended the full treatment course; improved follow-up after treatment: 143 of 237 (60%) patients who ended their full treatment were correctly monitored during the required period of 6 (cutaneous cases) or 12 (mucosal cases) months after the end of treatment. These achievements were largely due to the human and logistical resources made available, the constant availability of medications and the close collaboration between the Ministry of Health, a national research institute and an international non-governmental organization. At the end of this period, the health authorities decided to register a generic brand of sodium stibogluconate, which is now in use. This should allow the treatment of a significant number of additional patients, while saving money to invest in other facets of the case management.Publisher
Wiley-BlackwellPubMed ID
16135192Language
enISSN
1360-2276ae974a485f413a2113503eed53cd6c53
10.1111/j.1365-3156.2005.01460.x
Scopus Count
Collections
Related articles
- Patients' associations and the control of leishmaniasis in Peru.
- Authors: Guthmann JP, Calmet J, Rosales E, Cruz M, Chang J, Dedet JP
- Issue date: 1997
- [Research in tropical medicine and primary health care in Peru].
- Authors: Guerra H, Falconí E, Llanos-Cuentas A, Chang J
- Issue date: 1993 Sep-Oct
- Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru.
- Authors: Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, Miranda-Verastegui C, Santamaria-Castrellon G, Ramirez L, Lazo M, De Doncker S, Boelaert M, Robays J, Dujardin JC, Arevalo J, Chappuis F
- Issue date: 2008 Jan 15
- Mucosal leishmaniasis . Current scenario and prospects for treatment.
- Authors: Amato VS, Tuon FF, Bacha HA, Neto VA, Nicodemo AC
- Issue date: 2008 Jan
- Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.
- Authors: Arevalo J, Ramirez L, Adaui V, Zimic M, Tulliano G, Miranda-Verástegui C, Lazo M, Loayza-Muro R, De Doncker S, Maurer A, Chappuis F, Dujardin JC, Llanos-Cuentas A
- Issue date: 2007 Jun 15